Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Galderma begins 2 new clinical trials to investigate efficacy and safety of nemolizumab to treat patients with systemic sclerosis: Zug, Switzerland Friday, June 27, 2025, 13:00 Hr ...

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic autoimmune disorders known for causing severe muscle weakness, fatigue, and ...

Factbox-Vaccines and Antibodies up for Debate at CDC Advisory Panel Meeting (Reuters) -The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time ...